Thrombo ACS, 50 mg 100 pcs

Pharmaceutical group:

NAPs.

Pharmic action:

NPS. The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase, resulting in blocking the synthesis of thromboxane A2 and inhibiting platelet aggregation.

It is believed that there are other mechanisms of inhibition of platelet aggregation, which expands the field of its application in various vascular diseases.

It also has anti-inflammatory, analgesic and antipyretic effects.

Indications

– Prevention of acute myocardial infarction in the presence of risk factors (such as diabetes, hyperlipidemia, hypertension, obesity, smoking, old age);

– secondary prevention of myocardial infarction;

– unstable angina;
– stroke prevention (including.ч.
– prevention of transient cerebral circulatory disorders;
– prevention of thromboembolism after operations and invasive interventions on blood vessels (such as coronary artery bypass surgery, carotid endarterectomy, arterio-venous bypass surgery, carotid angioplasty);
– prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (e.g., in case of prolonged immobilization as a result of major surgical intervention).

Active ingredient

Composition

1 tablet:
– acetylsalicylic acid 50 mg or 100 mg

Supplementary substances:

Lactose,

Microcrystalline cellulose,
.

colloidal silicon dioxide,

potato starch,

talkp> talc,

triacetin,

silicone anti-foaming agent SE2,

How to take, the dosage

Trombo ACS tablets should be taken orally, without chewing, before meals, with a small amount of liquid.

It is prescribed orally at 50 to 100 mg once daily.

Trombo ASS® is intended for long-term use. The duration of therapy is determined individually.

Interaction

When used concomitantly, Thrombo ACC® increases the effect of the following medicines:

– methotrexate by reducing renal clearance and displacing it from protein binding;
– Heparin and indirect anticoagulants due to the deterioration of platelet function and displacement of indirect anticoagulants from protein binding;
– Thrombolytics and antiplatelet agents (ticlopidine);
– Hypoglycemic agents (insulin and sulfonylurea derivatives) due to high-dose hypoglycemic action of ASA itself and displacement of sulfonylurea derivatives from protein binding;
– Valproic acid due to its displacement from protein binding.

Additive effect is observed when concomitant administration of ASA with ethanol.

ASK attenuates the effects of uricosuric agents (benzbromaron) due to competitive tubular elimination of uric acid.
Concomitant use of GCS increases the excretion of salicylates and attenuates their effects.

Special Instructions

ASA may provoke bronchospasm, as well as causing attacks of bronchial asthma and other hypersensitivity reactions. Risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory diseases, and allergic reactions to other medications (itching, urticaria).

ASK can cause bleeding of varying severity during and after surgical interventions.

Combination of ASA with anticoagulants, thrombolytics, antiplatelet agents is accompanied by an increased risk of bleeding.

ASK in low doses may provoke development of gout in predisposed individuals with reduced excretion of uric acid.
Combination of ASK with methotrexate is accompanied by an increased frequency of side effects from the hematopoietic system.
High doses of ASK have hypoglycemic effect that should be considered when prescribing it to patients with diabetes mellitus who receive hypoglycemic drugs.

When prescribing in combination with GCS, it should be remembered that during treatment, blood levels of salicylates are decreased, and an overdose of salicylates is possible after withdrawal of GCS.

The combination of ASA with ibuprofen is not recommended because the latter worsens the beneficial effects of ASA on longevity.
When ASA is combined with alcohol, there is an increased risk of GI mucosal damage and prolonged bleeding time.

Contraindications

– “aspirin” asthma (bronchial asthma, induced by taking salicylates and NSAIDs);
– “aspirin triad” (combination of bronchial asthma and recurrent polyposis of the nose and sinuses). – Aspirin triad (combination of bronchial asthma, recurrent polyposis of nose and sinuses and intolerance to acetylsalicylic acid);
– Hemorrhagic diathesis;
– combined use with methotrexate at a dose of 15 mg or more per week;
– I and III trimesters of pregnancy;
– lactation (breastfeeding);
– Children and adolescents under 18 years of age;
– Hypersensitivity to acetylsalicylic acid, to the adjuvant substances of the preparation Thrombo-Assistance and other NSAIDs.

. With caution is administered in gout, hyperuricemia, in history of gastrointestinal ulcers or gastrointestinal bleeding, renal and hepatic failure, bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, allergic reactions to medicinal products in history, concurrent use with methotrexate in dose 15 mg or less per week.

Side effects

Allergic reactions: urticaria, Quincke’s edema, anaphylactic reactions.

Digestive system disorders: nausea, heartburn, vomiting, abdominal pain, gastric and duodenal ulcers (including perforative), increased activity of liver enzymes.

Respiratory system: bronchospasm.

Blood system disorders: anemia (rare), increased bleeding.

CNS disorders: dizziness, tinnitus.

In general, ThromboAss® is well tolerated by patients (due to the low content of acetylsalicylic acid in the drug). Side effects have been noted in single cases.

Overdose

Overdose is unlikely due to the low ASA content of the drug. An overdose of ASA is associated with a risk of gastrointestinal bleeding. Overdose is especially dangerous in elderly patients.

Symptoms: Nausea, vomiting, tinnitus, dizziness, confusion, general malaise.

Treatment: induced vomiting, administration of activated charcoal, laxatives; if necessary, correction of acid-base balance.

Similarities